GB virus C infection in children with perinatal human immunodeficiency virus infection

Academic Article


  • Background: GB virus C (GBV-C) infection occurs in 20-40% of human immunodeficiency virus (HIV)-infected adults, and coinfection is associated with improved HIV disease outcome. Methods: To determine the prevalence of GBV-C infection in children who were perinatally infected with HIV, we conducted a cross-sectional prevalence survey in a cohort of perinatally infected HIV-positive children selected from a large, multicenter observational protocol. A blood specimen was obtained and tested for GBV-C viremia with the use of a qualitative GBV-C RNA assay and screened for past GBV-C infection with enzyme-linked immunosorbent assay to detect antibodies to the GBV-C envelope protein E2 (E2 Ab). Results: The 354 children who participated in the substudy were relatively healthy, with a median CD4 of 784 cells/mm3 and median HIV-1 viral load of 1055 copies/mL. The prevalence of GBV-C viremia was 20 of 353 or 5.7% (95% confidence interval, 3.5-8.6%), and the prevalence of E2 Ab was 12 of 354 or 3.4% (95% confidence interval, 1.8-5.8%). GBV-C viremic patients were older than patients without past GBV-C infection (median age, 12.8 years versus 10.7 years). Median CD4+ lymphocyte counts were highest in subjects without GBV-C infection and lowest in those with E2 Ab. Conclusions: GBV-C prevalence rates are lower in children with perinatal HIV infection than those reported for HIV-infected adults. With the exception of evidence that GBV-C viremic children had lower rates of Centers for Disease Control and Prevention HIV disease category C disease before GBV-C testing, we did not find evidence of improved HIV disease outcome in coinfected patients, but the number of HIV/GBV-C-coinfected children was small. Copyright © 2005 by Lippincott Williams & Wilkins.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Schuval S; Lindsey JC; Stapleton JT; Van Dyke RB; Palumbo P; Mofenson LM; Oleske JM; Cervia J; Kovacs A; Dankner WN
  • Start Page

  • 417
  • End Page

  • 422
  • Volume

  • 24
  • Issue

  • 5